| INTERMUNE, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120101032 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI and VIa, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 04-26-2012 |
| 20120095211 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, Ia, II, IIa, III, IIIa, IIIb, IV, IVa, IVb, V, Va, Vb, VI, VIa, VIb, and VIc, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. The embodiments also provide methods for the synthesis of subject compounds and intermediates in the synthetic methods. | 04-19-2012 |
| 20120094897 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, and II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 04-19-2012 |
| 20120088801 | Pirfenidone Therapy and Inducers of Cytochrome P450 - The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. | 04-12-2012 |
| 20120077850 | PIRFENIDONE TREATMENT FOR PATIENTS WITH ATYPICAL LIVER FUNCTION - Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone. | 03-29-2012 |
| 20120046321 | METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS - The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF). | 02-23-2012 |
| 20120016133 | Method for Synthesizing Pirfenidone - A process for synthesizing pirfenidone from bromobenzene having less than about 0.15% by weight dibromobenze is disclosed. Also disclosed are processes of synthesizing pirfenidone without using ethyl acetate or n-butanol, and pirfenidone having controlled levels of ethyl acetate, n-butanol, di(5-methyl-2-pyridinone)benzenes, and other impurities having specified retention times. Also disclosed are formulated dosage forms including the disclosed pirfenidone. | 01-19-2012 |
| 20120015985 | Methods of Administering Pirfenidone Therapy - The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes. | 01-19-2012 |
| 20120015984 | Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients - A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need. | 01-19-2012 |
| 20120014917 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS - The invention relates to methods of treating patients infected with human immunodeficiency virus (HIV) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof. | 01-19-2012 |
| 20110319453 | Methods of Administering Pirfenidone Therapy - The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes. | 12-29-2011 |
| 20110312996 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 12-22-2011 |
| 20110263656 | Pirfenidone Treatment for Patients with Atypical Liver Function - Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone. | 10-27-2011 |
| 20110218169 | Pirfenidone/Toll-Like Receptor (TLR) Agonist Compounds and Methods of Treating Neutropenia - The invention disclosed herein relates to compositions and methods for treating subjects suffering from or at risk of developing neutropenia. In some embodiments, the methods comprise administering to a subject suffering from or at risk of developing neutropenia, an effective amount of pirfenidone and one or more toll-like receptor (TLR) agonists. | 09-08-2011 |
| 20110177026 | Use of Alpha-Glucosidase Inhibitors to Treat Alphavirus Infections - The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent. | 07-21-2011 |
| 20110172277 | PIRFENIDONE THERAPY AND INDUCERS OF CYTOCHROME P450 - The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. | 07-14-2011 |
| 20110166186 | METHODS OF ADMINISTERING PIRFENIDONE THERAPY - The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes. | 07-07-2011 |
| 20110152246 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 06-23-2011 |
| 20110136876 | Altering Pharmacokinetics of Pirfenidone Therapy - The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. | 06-09-2011 |
| 20110129444 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 06-02-2011 |
| 20110110890 | Novel Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formula I and compound 105S, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 05-12-2011 |
| 20110082182 | THERAPEUTIC ANTIVIRAL PEPTIDES - Disclosed herein are compounds represented by a formula: | 04-07-2011 |
| 20110081315 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, Ia, II, III, IV, V, VI-1, VI-2, VII, VIII, IX, X, XI, and XII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 04-07-2011 |
| 20110059047 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 03-10-2011 |
| 20110034495 | Method of Modulating Stress-Activated Protein Kinase System - A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders. | 02-10-2011 |
| 20110003863 | METHOD FOR SYNTHESIZING PIRFENIDONE - A process for synthesizing pirfenidone from bromobenzene having less than about 0.15% by weight dibromobenzene is disclosed. Also disclosed are processes of synthesizing pirfenidone without using ethyl acetate or n-butanol, and pirfenidone having controlled levels of ethyl acetate, n-butanol, di(5-methyl-2-pyridinone)benzenes, and other impurities having specified retention times. Also disclosed are formulated dosage forms including the disclosed pirfenidone. | 01-06-2011 |
| 20100324097 | Method of Providing Pirfenidone Therapy to a Patient - The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme. | 12-23-2010 |
| 20100221217 | THERAPEUTIC COMPOSITION - Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. | 09-02-2010 |
| 20100209391 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments also provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 08-19-2010 |
| 20100152250 | CAPSULE FORMULATION OF PIRFENIDONE AND PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS - A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need. | 06-17-2010 |
| 20100150867 | USE OF ALPHA-GLUCOSIDASE INHIBITORS TO TREAT ALPHAVIRUS INFECTIONS - The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent. | 06-17-2010 |
| 20100119479 | THERAPEUTIC ANTIVIRAL PEPTIDES - Disclosed herein are compounds represented by a formula: | 05-13-2010 |
| 20090318455 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS - Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system. | 12-24-2009 |
| 20090297476 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 12-03-2009 |
| 20090269305 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 10-29-2009 |
| 20090257979 | Novel Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 10-15-2009 |
| 20090220943 | HCV GENOTYPING AND PHENOTYPING - The present invention includes methods of genotyping and phenotyping HCV. In one embodiment, the methods of the invention can be used to determine whether a HCV isolate is resistant to an antiviral drug. The invention also includes primers for amplifying a HCV NS3 region and kits. | 09-03-2009 |
| 20090169510 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 07-02-2009 |
| 20090148407 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 06-11-2009 |
| 20090047246 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 02-19-2009 |
| 20080287508 | ALTERING PHARMACOKINETICS OF PIRFENIDONE THERAPY - The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl- | 11-20-2008 |
